RCMNY
HRTX icon

Rubric Capital Management (New York)’s Heron Therapeutics HRTX Stock Holding History

Rubric Capital Management (New York)’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.8M Hold
30,046,828
– – 0.12% 75
2026
Q1 		$24M Hold
30,046,828
– – 0.25% 61
2025
Q4 		$39.1M Buy
30,046,828
+946,100
+3% +$1.17M 0.47% 50
2025
Q3 		$36.7M Buy
29,100,728
+2,387,225
+9% +$3.78M 0.41% 46
2025
Q2 		$55.3M Hold
26,713,503
– – 0.84% 33
2025
Q1 		$58.8M Hold
26,713,503
– – 1.05% 28
2024
Q4 		$40.9M Hold
26,713,503
– – 0.52% 38
2024
Q3 		$53.2M Hold
26,713,503
– – 0.87% 32
2024
Q2 		$93.5M Hold
26,713,503
– – 2.45% 11
2024
Q1 		$74M Hold
26,713,503
– – 2.19% 14
2023
Q4 		$45.4M Hold
26,713,503
– – 0.94% 25
2023
Q3 		$27.5M Buy
26,713,503
+14,963,503
+127% +$21.3M 1.03% 30
2023
Q2 		$13.6M Hold
11,750,000
– – 0.58% 41
2023
Q1 		$17.7M Hold
11,750,000
– – 0.46% 46
2022
Q4 		$29.4M Buy
11,750,000
+9,233,672
+367% +$29.7M 1.28% 26
2022
Q3 		$10.6M Buy
+2,516,328
New +$9.85M 0.53% 45
2019
Q2 		– Sell
-1,500,000
Closed -$36.7M – 62
2019
Q1 		$36.7M Sell
1,500,000
-1,287,592
-46% -$33.7M 3.42% 9
2018
Q4 		$72.3M Buy
2,787,592
+828,742
+42% +$22.8M 8.95% 1
2018
Q3 		$62M Buy
1,958,850
+818,603
+72% +$30.5M 6.55% 3
2018
Q2 		$44.3M Sell
1,140,247
-369,761
-24% -$11.8M 4.35% 10
2018
Q1 		$41.7M Sell
1,510,008
-687,304
-31% -$15.6M 3.88% 10
2017
Q4 		$39.8M Buy
2,197,312
+297,312
+16% +$4.85M 4.91% 3
2017
Q3 		$30.7M Buy
1,900,000
+200,000
+12% +$3.14M 2.78% 6
2017
Q2 		$23.5M Buy
1,700,000
+100,000
+6% +$1.45M 4.85% 2
2017
Q1 		$24M Buy
1,600,000
+1,050,000
+191% +$14.5M 6.99% 2
2016
Q4 		$7.21M Buy
+550,000
New +$8.63M 2.48% 12

Other funds holding HRTX

CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rubric Capital Management (New York)'s HRTX Position: Q2 2026 in Review

Rubric Capital Management (New York) held its Heron Therapeutics (HRTX) position steady in Q2 2026 at 30,046,828 shares worth $12.8M. The position accounts for 0.12% of the portfolio, ranked #75.

Rubric Capital Management (New York) first reported a position in HRTX in Q4 2016 and has held it in 26 quarters since. The position peaked at $93.5M in Q2 2024. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Rubric Capital Management (New York) held 30,046,828 shares of Heron Therapeutics worth $12.8M as of Q2 2026.
  • Rubric Capital Management (New York) left its Heron Therapeutics share count unchanged in Q2 2026.
  • Heron Therapeutics made up 0.12% of Rubric Capital Management (New York)'s portfolio in Q2 2026, its #75 holding.
  • Rubric Capital Management (New York) first reported a position in Heron Therapeutics in Q4 2016 and has held it in 26 quarters since.
  • Rubric Capital Management (New York)'s Heron Therapeutics position peaked at $93.5M in Q2 2024.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2026, filed 14 Aug 2026.